Superficial Basal Cell Carcinoma

A phase 3 study of Ameluz and RhodoLED photodynamic therapy for superficial basal cell carcinoma has reached a key milestone as the final patient has completed the 1-year follow-up visit, Biofrontera announced in a press release.

The FDA has cleared AIV001 for testing for the treatment of facial skin with superficial and nodular superficial basal cell carcinoma, according to an AiViva Biopharma press release.

ORLANDO — Topical 5-fluorouracil and calcipotriene proved to be highly effective for superficial keratinocyte carcinomas, according to a presentation at the American Society for Dermatologic Surgery Annual Meeting.